News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Medsafe approves additional levothyroxine products

Media release

23 October 2008

Medsafe approves two additional levothyroxine products

The Ministry of Health's drug regulatory arm Medsafe has given provisional approval to two products containing levothyroxine. This will allow patients in New Zealand to have access to an approved alternative to Eltroxin.

The products are Synthroid, manufactured by Abbott Laboratories, which is also sold in Canada, and Levothyroxine, manufactured by Goldshield, which is also sold in the United Kingdom.

The provisional consent limits use of the products to initiation of treatment in new patients, and use in patients who are intolerant or unable to take another brand of levothyroxine. The Medsafe data sheets for the products will reflect these restrictions and each company will be required to notify prescribers and pharmacists of the increased need to closely monitor patients who switch brands of levothyroxine.

Medsafe group manager Dr Stewart Jessamine says "Following our evaluation of the data supplied in the applications, Medsafe is satisfied that both Levothyroxine and Synthroid are safe and effective alternatives to Eltroxin, however as neither application provided adequate evidence of bioequivalence use of these products will require careful monitoring if patients wish to avoid adverse effects."

Dr Jessamine said: "while changing to a new levothyroxine product will resolve many of the problems reported by patients taking Eltroxin, patients changing to these new brands will still need to have their blood tests monitored and are likely to require the dose of the new brand adjusted to suit their individual metabolism". PHARMAC Medical Director Dr Peter Moodie said the provisional consent given to the Goldshield brand means that it will be fully funded from 1 November. This was in line with the proposal PHARMAC consulted on from late September, he says. The existing funded brand of levothyroxine, Eltroxin, will also continue to be fully funded. PHARMAC has been able to put in place arrangements to ensure that when funding for Goldshield begins on 1 November, there will be sufficient stock to meet the expected demand. "We are very grateful to the efforts of Goldshield's supplier, Boucher & Muir, for getting stocks to New Zealand rapidly," said Dr Moodie. "We understand that stock is in the country this week, and will be distributed to wholesalers next week. This will ensure that should people require a prescription for Goldshield's brand of levothyroxine to be filled from 1 November, they will be able to do so." Dr Moodie says PHARMAC has no plans to fund Synthroid at this time, however it remains open to the possibility of funding it in the future.

Background

Full background to this issue, including a timeline, questions and answers and previous media releases is available by clicking the following link: http://www.moh.govt.nz/moh.nsf/indexmh/eltroxin?Open

ENDS

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Kakī: World’s Rarest Wading Bird Released In Mackenzie Basin

Conservation Minister Maggie Barry says the birds will add to the 60 released into the Tasman valley earlier this month, significantly boosting the wild population. More>>

ALSO:

IHC Tribute: Colin Meads

"While Colin is best known for rugby, to us he is one of a small number of distinguished IHC New Zealand Life Members recognised for their significant support for people with intellectual disabilities," says IHC Chief Executive Ralph Jones. More>>

ALSO:

Howard Davis Review: Tilting at Turbines - The Trip to Spain

Steve Coogan and Rob Brydon have now both broken the Big Fifty barrier, which seems to have brought a whole new level of angst to their midlife adventures ... More>>

Review: A Rose By Any Other Name Would Smell As Sweet

The Royal New Zealand Ballet has accepted the challenge of this heart-touching tragedy and largely succeeded. More>>

ALSO:

NZ's First Male IAAF Gold: Tom Walsh's Historic Shot Put Victory

Although feeling very sore but with a great feeling Tom Walsh took his place as number one on the victory dais to receive his much deserved gold medal. More>>

ALSO:

Scoop Review Of Books: Q&A: Hard To Find Books

"Unfortunately we are in crisis and this friendly dinosaur faces extinction… Our only hope is to try and raise funds to buy the building and restore it to its glory, either fully funded or with a viable deposit." More>>

 
 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland